First‑Line Trodelvy Gains FDA Approval as ASCENT‑03 Strengthens the Case for Earlier Use in Metastatic TNBC

  • Trodelvy now holds two FDA first‑line approvals in unresectable locally advanced or metastatic TNBC—as monotherapy for patients ineligible for PD‑1/PD‑L1 therapy, and in combination with pembrolizumab for PD‑L1–positive disease (CPS ≥10).
  • Phase 3 ASCENT‑03 data strengthened the push toward first‑line use, showing a clear PFS advantage for sacituzumab govitecan (9.7 vs. 6.9 months) and maintaining benefit even with crossover, prompting oncologists to reconsider long‑standing sequencing norms.
  •  Dr. Kevin Punie of University Hospitals Leuven, an investigator of the study, emphasizes that many metastatic TNBC patients never reach second‑line therapy, making upfront use of the most active agent clinically logical—particularly for those with aggressive, bulky, or high‑risk disease where attrition is common.

The FDA has granted two first‑line approvals for sacituzumab govitecan‑hziy (Trodelvy) in adults with unresectable locally advanced or metastatic triple‑negative breast cancer (TNBC).

  • Monotherapy: Trodelvy is now approved as a first‑line option for patients who are not candidates for PD‑1/PD‑L1 inhibitor–based therapy.
  • Combination therapy: Trodelvy may be used with pembrolizumab (Keytruda) — or pembrolizumab plus berahyaluronidase alfa‑pmph (Keytruda Qlex) — for patients whose tumors are PD‑L1–positive (CPS ≥10).

Since detailed phase 3 ASCENT-03 data were presented at the October 2025 ESMO Congress, a growing groundswell started building among breast oncologists around the use of sacituzumab govitecan (Trodelvy) as a first-line option for patients with metastatic triple-negative breast cancer.

The study’s results intensified conversations not about whether the drug outperforms standard chemotherapy, but whether clinicians were ready to move it earlier in the treatment sequence. As the data continue to be analyzed, the central question for clinicians is, “What will it take to make first-line use routine in appropriate patients?”

The phase 3 study evaluated whether the anti–TROP2 antibody-drug conjugate sacituzumab govitecan-hziy (Trodelvy) should be used upfront rather than reserved for later lines. According to Dr. Kevin Punie of University Hospitals Leuven, one of the study’s investigators, the results are increasingly difficult to ignore.

Superior Progression-Free Survival

ASCENT-03 demonstrated a clear progression-free survival (PFS) advantage when sacituzumab govitecan was used in the first-line setting.

  • Median PFS: 9.7 months with sacituzumab govitecan vs. 6.9 months with chemotherapy

Dr. Punie explained that the trial was intentionally designed to answer a clinically relevant question.

“In ASCENT-03, we tried to answer whether first-line anti–TROP2 ADC works better than second-line,” he said, noting that crossover to sacituzumab govitecan was incorporated so most patients in the control arm received the drug later.

Importantly, even with crossover, the benefit persisted. “The PFS2 analyses that show improvement for sacituzumab govitecan in first and second line are actually quite reassuring and important,” he said.

Why Timing Matters

While overall survival data continued to mature, Dr. Punie emphasized a key practical reality: up to half of patients with metastatic TNBC in real-world settings never receive second-line therapy.

“This is a very aggressive disease,” he said. “Not every patient makes it to second and certainly not to third line.”

That reality strengthened the argument for using the most effective therapy first. “It works better and longer than chemotherapy,” Dr. Punie said. “So it’s always the most logical scenario to position the treatment that has the highest likelihood to respond—or the longest duration of response—upfront.”

Which Patients Benefit Most?

Dr. Punie acknowledged that there may be select patients—such as those with late relapse or minimal, asymptomatic disease—where sequencing decisions remain nuanced. However, he stressed that these cases represent a minority.

For patients with bulky disease, short disease-free intervals, or those at risk of attrition, he believes the evidence now supports earlier use.

“For most patients,” he said, “positioning the anti–TROP2 ADC in first line is better.”